razuprotafib , Receptor-type tyrosine-protein phosphatase beta inhibitor, CAS No.1008510-37-9, Receptor-type tyrosine-protein phosphatase beta inhibitor

Item Number
R613105
Grouped product items
SKUSizeAvailabilityPrice Qty
R613105-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
R613105-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,897.90
View related series
RTP Type B Inhibitor

Basic Description

SynonymsCompound AA34 [US10220048] | AKOS040742534 | Razuprotafib [USAN] | RAZUPROTAFIB [WHO-DD] | N-(4-{(2S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido}-2-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]ethyl}phenyl)sulfamic acid | Razuprotafib | CS-0031483 | MS
Specifications & PurityMoligand™
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionReceptor-type tyrosine-protein phosphatase beta inhibitor

Product Properties

ALogP3.7

Associated Targets(Human)

PTPRB Tchem Receptor-type tyrosine-protein phosphatase beta (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name [4-[(2S)-2-[[(2S)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
INCHI InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
InChi Key KWJDHELCGJFUHW-SFTDATJTSA-N
Canonical SMILES COC(=O)N[C@H](C(=O)N[C@H](c1csc(n1)c1cccs1)Cc1ccc(cc1)NS(=O)(=O)O)Cc1ccccc1
Isomeric SMILES COC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)NS(=O)(=O)O)C3=CSC(=N3)C4=CC=CS4
PubChem CID 46700782
Molecular Weight 586.7

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, Kojima M, Xia H, Seidel C, Lima e Silva R et al..  (2014)  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature..  J Clin Invest,  124  (10): (4564-76).  [PMID:25180601] [10.1021/op500134e]

Solution Calculators